EVALUATION OF THE SAFETY, TOLERABILITY AND IMPACT ON BIOMARKERS OF ANTI-OXIDA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标 主要目的：评价两种抗氧化剂治疗轻中度阿尔茨海默病的安全性和耐受性，以及对脑脊液氧化损伤相关生物标志物的影响。 次要目的(S)：评价轻中度AD患者应用抗氧化剂后血浆和脑脊液中β-淀粉样蛋白-42和β-淀粉样蛋白-40浓度的变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Primary Objective: To assess the safety and tolerability, and effect on cerebrospinal fluid (CSF) biomarkers related to oxidative damage, of two antioxidant treatment regimens in patients with mild to moderate Alzheimer's disease. Secondary Objective(s): To assess whether concentrations of beta-amyloid-42 and beta-amyloid-40 in plasma and CSF change after administration of antioxidants in patients with mild to moderate AD.